This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- 9-aminocamptothecin
- DrugBank Accession Number
- DB12515
- Background
Aminocamptothecin has been used in trials studying the treatment of Lymphoma, Gastric Cancer, Ovarian Cancer, Esophageal Cancer, and Ovarian Neoplasms, among others.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for 9-aminocamptothecin (DB12515)
- Weight
- Average: 363.373
Monoisotopic: 363.121906039 - Chemical Formula
- C20H17N3O4
- Synonyms
- Aminocamptothecin
- External IDs
- NSC-603071
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbametapir The serum concentration of 9-aminocamptothecin can be increased when it is combined with Abametapir. Abatacept The metabolism of 9-aminocamptothecin can be increased when combined with Abatacept. Abemaciclib The metabolism of Abemaciclib can be decreased when combined with 9-aminocamptothecin. Acalabrutinib The metabolism of Acalabrutinib can be decreased when combined with 9-aminocamptothecin. Acenocoumarol The metabolism of Acenocoumarol can be decreased when combined with 9-aminocamptothecin. Acetaminophen The metabolism of 9-aminocamptothecin can be increased when combined with Acetaminophen. Acetazolamide The metabolism of 9-aminocamptothecin can be decreased when combined with Acetazolamide. Adalimumab The metabolism of 9-aminocamptothecin can be increased when combined with Adalimumab. Albendazole The metabolism of 9-aminocamptothecin can be decreased when combined with Albendazole. Aldesleukin The metabolism of 9-aminocamptothecin can be decreased when combined with Aldesleukin. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as camptothecins. These are heterocyclic compounds comprising a planar pentacyclic ring structure, that includes a pyrrolo[3,4-beta]-quinoline moiety (rings A, B and C), conjugated pyridone moiety (ring D) and one chiral center at position 20 within the alpha-hydroxy lactone ring with (S) configuration (the E-ring).
- Kingdom
- Organic compounds
- Super Class
- Alkaloids and derivatives
- Class
- Camptothecins
- Sub Class
- Not Available
- Direct Parent
- Camptothecins
- Alternative Parents
- Aminoquinolines and derivatives / Pyranopyridines / Pyridinones / Benzenoids / Tertiary alcohols / Heteroaromatic compounds / Amino acids and derivatives / Carboxylic acid esters / Lactones / Lactams show 8 more
- Substituents
- Alcohol / Amine / Amino acid or derivatives / Aminoquinoline / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Camptothecin / Carbonyl group / Carboxylic acid derivative show 20 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- pyranoindolizinoquinoline (CHEBI:80755)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 5MB77ICE2Q
- CAS number
- 91421-43-1
- InChI Key
- FUXVKZWTXQUGMW-FQEVSTJZSA-N
- InChI
- InChI=1S/C20H17N3O4/c1-2-20(26)13-7-16-17-10(6-11-14(21)4-3-5-15(11)22-17)8-23(16)18(24)12(13)9-27-19(20)25/h3-7,26H,2,8-9,21H2,1H3/t20-/m0/s1
- IUPAC Name
- (19S)-8-amino-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione
- SMILES
- CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=CC=C(N)C1=C3)C2=O
References
- General References
- Not Available
- External Links
- KEGG Compound
- C16822
- PubChem Compound
- 72402
- PubChem Substance
- 347828746
- ChemSpider
- 65333
- BindingDB
- 50008936
- ChEBI
- 80755
- ChEMBL
- CHEMBL274070
- ZINC
- ZINC000037866089
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Treatment Esophageal Cancer / Malignant Neoplasm of Stomach 1 2 Completed Treatment Lung Cancers 1 2 Completed Treatment Malignant Lymphomas 2 2 Completed Treatment Neoplasms, Ovarian 1 2 Completed Treatment Ovarian Cancer 1 2 Completed Treatment Ovarian Cancer / Primary Peritoneal Cavity Cancer 1 2 Completed Treatment Renal Cancers 1 1 Completed Treatment Acute Lymphoblastic Leukemia (ALL) / Leukemia, Myelocytic, Acute 1 1 Completed Treatment Malignancies 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.633 mg/mL ALOGPS logP 1.35 ALOGPS logP 0.39 ChemAxon logS -2.8 ALOGPS pKa (Strongest Acidic) 11.71 ChemAxon pKa (Strongest Basic) 3.91 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 105.75 Å2 ChemAxon Rotatable Bond Count 1 ChemAxon Refractivity 99.19 m3·mol-1 ChemAxon Polarizability 37.87 Å3 ChemAxon Number of Rings 5 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Maier-Salamon A, Thalhammer T, Reznicek G, Bohmdorfer M, Zupko I, Hartl A, Jaeger W: Cytochrome P450 3A-mediated metabolism of the topoisomerase I inhibitor 9-aminocamptothecin: impact on cancer therapy. Int J Oncol. 2014 Aug;45(2):877-86. doi: 10.3892/ijo.2014.2473. Epub 2014 May 29. [Article]
Drug created at October 20, 2016 22:40 / Updated at June 12, 2020 16:53